Shenzhen Mindray Bio-Medical A/H Listing-Strong Track Record but Has Been Suffering Lately
Shenzhen Mindray Bio-Medical Electronics (300760 CH) (SMBE), a provider of medical devices, is looking to raise about US$2bn in its upcoming H...
305 Views
3SBio Inc (1530 HK) Placement - The Placing Price Indicates Decent Upside Potential in Valuation
3SBio's valuation logic shifting away from Mandi, focusing on innovative drug R&D for future growth and potential to surpass peers with good...
257 Views
Mandi Pre-IPO Tearsheet
Mandi, a specialized consumer pharmaceuticals company in China, plans to raise up to US$200m in its Hong Kong IPO with Huatai.
183 Views
Pre-IPO Mandi Inc. - The Business Model, the Concerns and the Valuation
Mandi's short-term success hinges on Minoxidil, but uncertainty looms with Winlevi and semaglutide. Growth may slow due to VBP and competition. A...
217 Views
3SBio (1530 HK) Placement: 3SBio’s Pipeline Strength, An Indirect Stake in Mandi Makes It Attractive
3SBio Inc announces placement of 105.2M shares at HK$29.62/share for R&D and working capital. Placement attractive given 3SBio's pipeline...
216 Views